Warwick Warp is pleased to announce the appointment of a new Chief Executive Officer, Mr Andrew Waterfall. Andrew joins the company at an exciting time in its history, having recently secured substantial new investment for future research and development.

Andrew has held several sales and managerial roles relating to biological software products. He has an Honours degree in Genetics and spent two years as a Clinical Cytogeneticist for the NHS after leaving University. In 1990, Andrew became a founding partner and CEO of Improvision Ltd., which under his direction, became a global leader in software and systems for biological imaging. Andrew successfully completed the sale of Improvision in 2007 to the PerkinElmer group, a $1.5bn turnover company.

Highly experienced in product and sales development, Andrew has joined the company to ensure that Warwick Warp can capitalise on its unique biometric technology and bring to fruition the commercial potential that its innovations can undoubtedly deliver.

Commenting on Andrew's appointment, Terry Swainbank, Investment Director of Synergis Technologies, part of the Porton Capital Group, the lead investor into Warwick Warp said "I am delighted that Andrew has joined Warwick Warp. As CEO of a highly successful multi-national software imaging company, Andrew has demonstrated his capability as a successful entrepreneur and business manager. His strong commercial background together with extensive knowledge of the European and US software markets will make him a valuable addition to the Warwick Warp team".